Vertigo Treatment Market Analysis

Global Vertigo Treatment Market Overview

The Vertigo Treatment Market Size was valued at USD 1.45 Billion in 2023. The Global Vertigo Treatment industry is projected to grow from USD 1.52 Billion in 2024 to USD 2.15 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.67% during the forecast period (2024 - 2032). Vertigo is a sense of spinning dizziness that can be caused by problems in the brain or inner ear, including sudden head movements, or inflammation in the inner ear due to a viral or bacterial infection. Vertigo can be treated with medications such as steroids that can reduce internal ear inflammation, and water pills that can reduce fluid buildup in the ear.

In June 2024, Altamira Therapeutics Ltd., a biopharmaceutical business, has highlighted a peer-reviewed article that supports the use of betahistine for treating lingering dizziness in patients with benign paroxysmal positional vertigo (BPPV). BPPV, which stands for Benign Paroxysmal Positional Vertigo, is the most common type of vertigo. It imposes a significant financial burden on the U.S. healthcare system, with an annual cost of about $2 billion. Frequently, it hampers daily tasks and job performance as a result of symptoms provoked by alterations in head position. Despite the effectiveness of repositioning maneuvers such as the Epley maneuver, a significant proportion of patients (up to 61%) may still suffer from persistent dizziness, which can have a negative influence on their overall quality of life. Betahistine is not currently accessible in the United States, although it is utilized in approximately 115 other countries for the treatment of vertigo and Meniere's disease. Altamira is now working on the development of AM-125, which is a nasal spray containing betahistine. This nasal spray is being created in order to overcome the issue of betahistine's limited oral bioavailability. AM-125 has exhibited a bioavailability that is up to 29 times more than its oral equivalent, and has displayed potential in a Phase 2 clinical trial for the treatment of acute vestibular syndrome (AVS). The company, which is shifting its focus towards RNA delivery technology, is seeking to collaborate or sell off its AM-125 initiative. The CEO of Altamira, Dr. Thomas Meyer, expressed confidence in the potential of AM-125 for treating BPPV and the company's dedication to providing betahistine to patients in the United States.

In May 2024, an Irish medical technology start-up Vertigenius has successfully secured over €2.1 million in a seed fundraising round for their wearable head sensor and software, which is specifically designed to enhance the treatment of vertigo. The funding round, which received more investment requests than available funds, will provide Vertigenius with the necessary capital to generate 10 additional employment opportunities and extend its operations into the markets of the United Kingdom and the United States. Vertigo is a prevalent symptom of an underlying disease that causes a patient to have a sensation of spinning in their surroundings. This condition mostly arises from an issue within the inner ear, which consequently impacts an individual's sense of balance. The majority of patients experience a full recovery following their sessions with a vestibular therapist and diligently completing the recommended exercises at home. Vertigenius asserts that a dearth of specialists in the field frequently hinders the promptness of medical intervention, perhaps rendering it unattainable. The intricacy of workouts might also pose challenges in the therapeutic process. The business, located in Dublin, has created a wearable head sensor and software that enables therapists to prescribe and monitor exercises performed by patients, observe their symptoms, and analyze the efficacy of therapies. An application linked to the sensor provides users with real-time guidance on performing exercises correctly and monitoring symptoms.

The increasing initiatives by public and private companies influence the market growth positively. The ever-increasing number of clearances and product launches by key players in the market are likely to act as a promising factor for the vertigo teatment market growth in the near future.

Vertigo Treatment Market Drivers

• Increase in prevalence of vertigo cases
  
  
  
  • Cases of vertigo are on the rise, with over 20% 50% of the global population affected by vertigo and According to the National Center for Biotechnology Information, in the US, around 26 million people required a visit to an emergency department for dizziness/vertigo.
  
  
  
  


• Rapid technological advancements


• Rise in healthcare expenditure


• Increasing geriatric population


• Increasing mergers & acquisitions by prominent market players in the vertigo treatment


• Growing initiatives to create awareness
  
  
  
  • For instance, the German Center for Vertigo and Balance Disorders (DSGZ) started an initiative called DIZZYNET. The main aim is to create a platform for collaboration and exchange among scientists, physicians, and physiotherapists to understand the treatment options and epidemiology of vertigo. Such initiates help to create awareness regarding symptoms and treatment for vertigo.
  
  
  
  

Vertigo Treatment Market Restraints

• Lack of information about the symptoms and causes of vertigo

Vertigo Treatment Market Segment Insights

Vertigo Treatment Type Insights

• 
  

  Benign Paroxysmal Positional Vertigo (BPPV): Expected to hold the largest share, as benign paroxysmal positional vertigo is the most common form of peripheral vertigo. This type tends to cause short, frequent bouts of vertigo.

  
  


• 
  

  Labyrinthitis: An inner ear infection causes labyrinthitis form of vertigo. This form of vertigo is usually overlooked as they appear with other symptoms such as fever and earache.

  
  


• 
  

  Vestibular Neuronitis: Vestibular neuritis is a disorder that affects the nerve of the inner ear. This type of vertigo has a sudden onset and may cause unsteadiness, earache, nausea, and vomiting.

  
  


• 
  

  Meniere’s disease: This type of vertigo is often so severe that it causes nausea and vomiting. Meniere’s disease also causes hearing loss, ringing in your ears, and a feeling of fullness in your ears.

  
  

Vertigo Treatment Treatment Insights

• 
  

  Anticholinergics: Anticholinergics are vestibular suppressants and are most important in treating vertigo since anticholinergic drugs that do not cross the blood-brain barrier are ineffective in controlling motion sickness. The most effective single anticholinergic drug for the prophylaxis and treatment of motion sickness is scopolamine. All anticholinergics conventionally used in the management of vertigo or motion sickness have prominent side-effects, often including dry mouth, dilated pupils, and sedation. Anticholinergics are ineffective if administered after symptoms have already appeared.

  
  


• 
  

  Antihistamines: Centrally acting antihistamines prevent motion sickness and reduce the severity of symptoms, even if taken after the onset of the symptoms. All the antihistamines in general use for control of vertigo also have anticholinergic activity.

  
  


• 
  

  Benzodiazepines: Benzodiazepines are extremely useful for the management of acute vertigo. They are also helpful in controlling motion sickness and can also minimize anxiety and panic associated with vertigo. Diazepam, clonazepam, lorazepam, and alprazolam are commonly prescribed benzodiazepines for their effect as anxiolytics and antidepressants.

  
  


• 
  

  Others: The other segment includes antibiotics and other drugs that can help ease the symptoms of vertigo.

  
  

Vertigo Treatment End-User Insights

• 
  

  Hospital: Hospitals dominate the global market for vertigo treatment. The positive growth of hospitals is attributed to their rising need to offer treatments for various health disorders. Additionally, the large number of hospitals is also driving the growth for the hospital's segment.

  
  


• 
  

  Clinics: Clinics take up the second-largest share due to the rising number of clinics and the increasing patient population.

  
  

Vertigo Treatment Regional Insights

• 
  

  Americas:It is the largest regional vertigo treatment market owing to the large patient population, rise in prevalence of vertigo, and surge in awareness about the causes of vertigo and its treatments. According to the American Speech-Language-Hearing Association, around 40% of the population in the US experience some form of dizziness or balance difficulty over the course of a lifetime.

  
  


• 
  

  Europe:The growing presence of the developed pharmaceutical industry and the significant demand for vertigo related therapeutics is driving the market growth of the vertigo treatment in Europe. According to the National Center for Biotechnology Information, the prevalence of vertigo in Germany was 22.9%.

  
  


• 
  

  Asia-Pacific:The Asia-Pacific region is anticipated to be the fastest-growing region in the global market of vertigo treatment. This region has witnessed a surge in the number of people afflicted with vertigo and other neurological disorders.

  
  


• 
  

  Middle East & Africa:The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.

  
  

Vertigo Treatment Market Key Players

• Hoffmann-La Roche (Switzerland)


• GlaxoSmithKline (UK)


• Novartis (Switzerland)


• Pfizer (US)


• Teva Pharmaceutical (Israel)


• Sanofi (France)


• AstraZeneca (UK)


• Intas Pharmaceutical Ltd (India)


• Sun Pharmaceutical Industries Ltd (India)